347 related articles for article (PubMed ID: 9002773)
21. Studies on radiolabeled somatostatin analogues in rats and in patients.
Breeman WA; Bakker WH; De Jong M; Hofland LJ; Kwekkeboom DJ; Kooij PP; Visser TJ; Krenning EP
Q J Nucl Med; 1996 Sep; 40(3):209-20. PubMed ID: 8961800
[TBL] [Abstract][Full Text] [Related]
22. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.
van der Harst E; de Herder WW; Bruining HA; Bonjer HJ; de Krijger RR; Lamberts SW; van de Meiracker AH; Boomsma F; Stijnen T; Krenning EP; Bosman FT; Kwekkeboom DJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):685-93. PubMed ID: 11158032
[TBL] [Abstract][Full Text] [Related]
23. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma.
Leners N; Jamar F; Fiasse R; Ferrant A; Pauwels S
J Nucl Med; 1996 Jun; 37(6):916-22. PubMed ID: 8683311
[TBL] [Abstract][Full Text] [Related]
24. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
25. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
26. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
27. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.
McCarthy KE; Woltering EA; Espenan GD; Cronin M; Maloney TJ; Anthony LB
Cancer J Sci Am; 1998; 4(2):94-102. PubMed ID: 9532411
[TBL] [Abstract][Full Text] [Related]
28. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
29. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue.
Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B
Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846
[TBL] [Abstract][Full Text] [Related]
30. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
31. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
[TBL] [Abstract][Full Text] [Related]
32. Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.
Bombardieri E; Seregni E; Savelli G; Villano C; Castellani MR; Cirillo F; Pallotti F; Fracassi S; Chiesa C; Chiti A; Bajetta E
J Endocrinol Invest; 2003; 26(8 Suppl):63-9. PubMed ID: 15233216
[No Abstract] [Full Text] [Related]
33. [Present status and progress of endocrine nuclear medicine].
Nakajo M
Kaku Igaku; 1999 Jan; 36(1):1-5. PubMed ID: 10087759
[TBL] [Abstract][Full Text] [Related]
34. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor?
Kropp J; Hofmann M; Bihl H
Anticancer Res; 1997; 17(3B):1583-8. PubMed ID: 9179198
[TBL] [Abstract][Full Text] [Related]
35. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
36. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
38. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy.
Virgolini I; Traub T; Leimer M; Novotny C; Pangerl T; Ofluoglu S; Halvadjieva E; Smith-Jones P; Flores J; Li SR; Angelberger P; Havlik E; Andreae F; Raderer M; Kurtaran A; Niederle B; Dudczak R
Q J Nucl Med; 2000 Mar; 44(1):50-8. PubMed ID: 10932601
[TBL] [Abstract][Full Text] [Related]
39. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
40. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Bal CS; Gupta SK; Zaknun JJ
Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
